Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Operations (2016 - 2025)

Historic Cash from Operations for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • NovaBay Pharmaceuticals' Cash from Operations rose 2465.19% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 1568.09%. This contributed to the annual value of -$5.2 million for FY2024, which is 2163.81% down from last year.
  • According to the latest figures from Q3 2025, NovaBay Pharmaceuticals' Cash from Operations is -$1.8 million, which was up 2465.19% from -$3.0 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' 5-year Cash from Operations high stood at $638000.0 for Q4 2024, and its period low was -$4.3 million during Q4 2021.
  • In the last 5 years, NovaBay Pharmaceuticals' Cash from Operations had a median value of -$1.7 million in 2022 and averaged -$1.7 million.
  • The largest annual percentage gain for NovaBay Pharmaceuticals' Cash from Operations in the last 5 years was 18836.57% (2024), contrasted with its biggest fall of 27801.86% (2024).
  • Over the past 5 years, NovaBay Pharmaceuticals' Cash from Operations (Quarter) stood at -$4.3 million in 2021, then surged by 72.0% to -$1.2 million in 2022, then skyrocketed by 40.28% to -$722000.0 in 2023, then soared by 188.37% to $638000.0 in 2024, then crashed by 388.4% to -$1.8 million in 2025.
  • Its last three reported values are -$1.8 million in Q3 2025, -$3.0 million for Q2 2025, and -$1.3 million during Q1 2025.